| Drug General Information |
| Drug ID |
D0S2VD
|
| Former ID |
DNCL003460
|
| Drug Name |
Ibrutinib companion diagnostic
|
| Indication |
Chronic lymphocytic leukaemia [ICD10:C91]
|
Approved |
[1]
|
|---|
| Company |
Abbott Laboratories; Janssen Biotech; Pharmacyclics
|
| Target and Pathway |
| Target(s) |
Tyrosine-protein kinase BTK |
Target Info |
Inhibitor |
[2]
|
|---|
|
KEGG Pathway
|
NF-kappa B signaling pathway
|
|
Osteoclast differentiation
|
|
Platelet activation
|
|
B cell receptor signaling pathway
|
|
Fc epsilon RI signaling pathway
|
|
Primary immunodeficiency
|
|
PANTHER Pathway
|
B cell activation
|
|
Pathway Interaction Database
|
Fc-epsilon receptor I signaling in mast cells
|
|
BCR signaling pathway
|
|
FAS (CD95) signaling pathway
|
|
Class I PI3K signaling events
|
|
EPO signaling pathway
|
|
PathWhiz Pathway
|
Fc Epsilon Receptor I Signaling in Mast Cells
|
|
Reactome
|
MyD88:Mal cascade initiated on plasma membrane
|
|
Regulation of actin dynamics for phagocytic cup formation
|
|
DAP12 signaling
|
|
FCERI mediated Ca+2 mobilization
|
|
MyD88 deficiency (TLR2/4)
|
|
IRAK4 deficiency (TLR2/4)
|
|
RHO GTPases Activate WASPs and WAVEs
|
|
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
|
|
WikiPathways
|
Kit receptor signaling pathway
|
|
MyD88:Mal cascade initiated on plasma membrane
|
|
Signaling by the B Cell Receptor (BCR)
|
|
DAP12 interactions
|
|
B Cell Receptor Signaling Pathway
|
|
TSLP Signaling Pathway
|
|
Regulation of toll-like receptor signaling pathway
|
|
IL-5 Signaling Pathway
|
| References |
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 |
|---|
| REF 2 | Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials. Curr Hematol Malig Rep. 2013 Mar;8(1):1-6. |
|---|
